INTRODUCTION

Skin, which is the largest organ in the human body, accounts for almost 15% of the total adult bodyweight. It protects the organism from environmental stresses, such as dehydration, irradiation, mechanical trauma and pathogenic infection. The essential functions of skin rely on its stratification, the adhesion level between layers and different cell types and various signals that fine-tune gene expression which maintains skin homeostasis. Previously, lots of researches have described the involvement of coding genes in skin development and diseases.1,2 However, the regulatory roles of non-coding genes in skin biology and diseases still need to be further elucidated.

Abstract

Advances in transcriptome sequencing have revealed that the genome fraction largely encodes for thousands of non-coding RNAs. Long non-coding RNAs (lncRNAs), which are a class of non-protein-coding RNAs longer than approximately 200 nucleotides in length, are emerging as key epigenetic regulators of gene expression recently. Intensive studies have characterized their crucial roles in cutaneous biology and diseases. In this review, we address the promotive or suppressive effects of lncRNAs on cutaneous physiological processes. Then, we focus on the pathogenic role of dysfunctional lncRNAs in a variety of proliferative skin diseases. These evidences suggest that lncRNAs have indispensable roles in the processes of skin biology. Additionally, lncRNAs might be promising biomarkers and therapeutic targets for cutaneous disorders.
Advances in high-throughput deep sequencing of the transcriptome and the ENCODE project over the last two decades have demonstrated that only approximately 2% of the genome codes for proteins, while the largest genome fraction encodes for thousands of non-coding RNAs. These results indicate that non-coding RNAs, which were considered as "transcriptional noises," play a critical role in the gene control across all kingdoms of life.

According to the length of transcripts, modulatory non-coding RNAs can be categorized into two distinct classes: small (such as microRNAs) and long non-coding RNAs (lncRNAs). LncRNAs are a large and diverse class of non-coding RNA molecules defined as non–protein-coding RNAs that are >200 nucleotides in length. Previous studies have certified that lncRNAs almost participated in all aspects of biological behaviours, such as epigenetics, transcription, and post-transcription. Additionally, they are proved to be involved in biological processes both physiologically and pathologically.

Recently, researchers have taken advantage of microarray and high-throughput deep sequencing to further explore the regulatory effects of lncRNAs in the field of cutaneous research. Emerging evidence indicates that lncRNAs not only play an essential role in the biology of skin development but also in the pathology of cutaneous proliferation-related diseases. In this review, we summarize an overview of current knowledge regarding the roles of lncRNAs in skin biology and disease, discussing the challenges and the potential clinical applications that they offer.

2 | LNCRNA CLASSIFICATION AND REGULATORY MECHANISMS

LncRNAs can be grouped according to the genomic location from which they are transcribed (Figure 1). For example, enhancer lncRNAs originate from enhancer regions, and promoter-associated lncRNAs are transcribed in the opposite direction to the protein-coding transcript from regions in close proximity to a promoter. In addition, intergenic lncRNAs are transcribed from non-coding DNA sequences located between protein-coding genes, whereas intronic lncRNAs are transcribed from the introns of protein-coding genes. Sense lncRNAs and natural antisense lncRNAs are transcribed from the sense and antisense strands of protein-coding genes, respectively. Additionally, sense lncRNAs and natural antisense lncRNAs can overlap with one or several introns and/or exons of the sense sequence. Untranslated region (UTR) overlapping lncRNAs are transcribed from DNA sequences overlapping the 3′ UTR or 5′ UTR region of a protein-coding gene in the sense strand (Figure 1).

LncRNAs modulate gene expression by interacting with DNA, RNA or proteins via structural interactions and/or complementary base pairing. They can regulate gene expression in multiple ways, including epigenetic modification, transcription, post-transcription, translation and post-translation. For example, epigenetic control by lncRNAs, such as X inactivation, genomic imprinting, mediation of mRNA stability enhancement or decay, and neutralization of miRNAs, has been reported. At the transcriptional level, lncRNAs play activator roles in enhancing or inhibiting protein-coding gene transcription. These lncRNAs are usually synthesized at enhancers. They influence the activity of enhancers or recruit protein complexes to enhancers, acting as cofactors that help remodel chromatin architecture and enhance kinase activity. At the post-transcriptional level, lncRNAs regulate diverse processes, such as transport, translation, splicing or decay of mRNA and neutralization of miRNAs.

Recently, growing evidence indicates that lncRNAs exert important effects on the biological processes of cutaneous development as well as on the pathogenesis of skin diseases via multiple ways mentioned above.

3 | THE INDISPENSABLE ROLES OF LNCRNAS IN CUTANEOUS BIOLOGY

According to the physiological structural anatomy, the skin consists of three primary layers: epidermis, dermis and hypodermis.
The epidermis, the top layer of skin, encompasses distinct layers of keratinocytes, including the basal layer (stratum basale), the squamous cell layer (stratum spinosum), the granular layer (stratum granulosum) and the cornified layer (stratum corneum). Melanocytes reside in the bottom layer of the epidermis. Additionally, hair follicles extend from the deeper dermal tissue, through the basement membrane and epithelial layer and extend beyond the border of the skin.

**Figure 2** The structure of the epidermis and dermis. Epidermal skin encompasses distinct layers of keratinocytes, including the basal layer (stratum basale), the squamous cell layer (stratum spinosum), the granular layer (stratum granulosum) and the cornified layer (stratum corneum). Melanocytes reside in the bottom layer of the epidermis. Additionally, hair follicles extend from the deeper dermal tissue, through the basement membrane and epithelial layer and extend beyond the border of the skin.

**Figure 3** Schematic diagram of functional lncRNAs in cutaneous biology. LncRNAs function as promoters or suppressors in diverse skin physiological processes, including keratinocytes differentiation, melanocyte function, hair growth and wound healing. Red arrow indicates upregulation. Green arrow represents downregulation. Black arrow indicates promotion. White means the abrogation of upstream inhibition.

- **TINCR**
- **ANCR**
- **H19**
- **UCA1**
- **SPRY4TL**
- **CREB/MITF/Melanogenesis**
- **DNMTs**
- **DPPIV**
- **MCM2**

- **Keratinocyte differentiation**
- **Melanocyte function**
- **Hair growth**
- **Wound healing**

**ANCR**, anti-differentiation ncRNA; **ANRIL**, antisense non-coding RNA in the INK4 locus; **CREB**, cAMP-responsive element-binding protein; **DNMTs**, DNA methyltransferases; **DPPIV**, dipeptidyl peptidase IV; **E2F1**, E2F transcription factor 1; **EZH2**, enhancer of zeste homolog 2; **HIF-1α**, hypoxia-inducible factor 1 subunit alpha; **HOTAIR**, HOX transcript antisense RNA; **MiTF**, microphthalmia-associated transcription factor; **Prox1**, Prospero homeobox 1; **SPRY4TL**, SPRY4 intronic transcript 1; **STAU1**, staufen double-stranded RNA binding protein 1; **TGF-β1**, transforming growth factor beta 1; **TINCR**, terminal differentiation–induced ncRNA; **UCA1**, urothelial cancer associated 1; **WAKMAR1**, wound and keratinocyte migration–associated lncRNA 1.
TABLE 1 Functional LncRNAs in cutaneous biology

| LncRNAs   | Class          | Length (bp) | Location         | Functions                      | Targets                        | Ref. |
|-----------|----------------|-------------|------------------|-------------------------------|-------------------------------|------|
| TINCR     | Intronic       | 3733        | Nucleus and Cytoplasm | Keratinocyte differentiation | STAU1                         | 48   |
| ANCR      | Intergenic     | 855         | Cytoplasm        | Keratinocyte differentiation  | EZH2/PRC2                     | 49   |
| H19       | Intergenic     | 2322        | Nucleus          | Keratinocyte differentiation  | miR 130b 3p-Dsg1              | 50   |
| SPRIGHTLY | Intronic       | 703         | Cytoplasm        | Melanocyte proliferation      | MCM2/DPPIV                    | 53   |
| UCA1      | Intergenic     | 2314        | Cytoplasm        | Melanogenesis                 | CREB/MiTF                     | 54   |
| PlncRNA 1 | Antisense      | 743         | Cytoplasm        | Hair growth                   | TGF/β1-Wnt/β-catenin           | 56   |
| H19       | Intergenic     | 2322        | Nucleus          | Hair follicle induction       | Wnt/β-catenin                 | 57   |
| RP11-766N7.3 | Intergenic    | 557         | Nucleus          | Hair follicle induction       | Wnt/β-catenin                 | 57   |
| HOTAIR    | Antisense      | 2364        | Nucleus and Cytoplasm | Hair follicle induction     | Wnt/β-catenin                 | 57   |
| WAKMAR1   | Unclassified   | 20700       | Nucleus          | Wound healing                 | DNMTs/E2F1                    | 60   |
| H19       | Intergenic     | 2322        | Nucleus          | Wound healing                 | EZH2/HIF-1α                   | 61   |
| ANRIL     | Antisense      | 2659        | Nucleus and Cytoplasm | Wound healing                | miR-181a/Prox1                | 62   |

Cells, dendritic cells and fibroblasts. Additionally, hair follicle morphogenesis occurs via interactions between epidermal keratinocytes and dermal fibroblasts (Figure 2).

Previous studies majorly focused on the modulatory effects of microRNAs on the processes of keratinocytes’ proliferation and differentiation, melanocytes biology, hair growth and wound healing. In recent years, emerging evidence has indicated that LncRNAs, another kind of non-coding RNAs, are also involved in these physiological processes (Figure 3; Table 1).

3.1 LncRNAs regulate keratinocyte differentiation

The epidermis is a stratified surface epithelium that provides a barrier to the external environment. Physiologically, the human epidermis continuously renews itself approximately every 4 weeks by a process of keratinocyte migration, proliferation and differentiation. During the course of epidermal differentiation, a subset of basal keratinocytes withdraws from the cell cycle, detaches from the basement membrane, migrates through the epidermis and undergoes terminal differentiation. A precise balance between the progenitor compartment and terminally differentiated layers is of great importance for the maintenance of the functional epidermis.

To determine the effects of LncRNA on the differentiation of keratinocyte, studies profiled LncRNA expression by microarray and validated the results by qRT-PCR in the differentiating human keratinocytes using a three-dimensional epidermal equivalent. In this model, LncRNA BC020554 was found to be downregulated upon keratinocyte differentiation. In contrast, LncRNA AK022798 was upregulated for early keratinocyte differentiation. However, the biological functions of these differential LncRNAs remain to be elucidated.

Terminal differentiation-induced ncRNA (TINCR), a 3.7 kb nuclear and cytoplasmic intronic LncRNA, was found to control the human epidermal differentiation in vitro by a post-transcriptional mechanism in differentiated keratinocytes. Research has revealed that TINCR interacts with a range of differentiation mRNAs through a 25-nucleotide “TINCR box” motif, which can better help them bind to the staufen double-stranded RNA binding protein 1 (STAU1) protein, increasing their stabilization in differentiated epidermal strata.

Anti-differentiation ncRNA (ANCR), another well-characterized 855 bp cytoplasmic intergenic LncRNA, was downregulated during the terminal differentiation of keratinocytes, adipocytes and osteoblasts in organotypic human tissues. Contrary to TINCR, ANCR repressed keratinocyte differentiation by associating with the methyltransferase enhancer of zeste homolog 2 (EZH2) and acting as a guide for the polycomb repressive complex 2 (PRC2) chromatin-modifying complex that eventually leads to epigenetic silencing of target gene loci.

LncRNA H19, a 2322 bp nuclear intergenic LncRNA, promoted the keratinocyte differentiation process in primary human keratinocytes from fresh post-operative skin samples of children. Mechanically, H19 acted as an endogenous “sponge,” which bound directly to miR-130b-3p. This sponge directly decreased the activity of miR-130b-3p and consequently increased the expression of miR-130b-3p downstream target desmoglein-1 (Dsg1), resulting in the promotion of keratinocyte differentiation.

Summarily, these results indicate that LncRNAs have both pro-differentiation (such as TINCR and H19) and anti-differentiation (such as ANCR) effects on the processes of keratinocyte differentiation via diverse mechanisms. Further studies are needed to explore the precise roles of LncRNAs in regulating keratinocyte differentiation.

3.2 LncRNAs modulate melanocyte functions

Melanocytes, which are located in the basal layer, make up 8% of the epidermis. They produce melanin pigment, which determines the colour of the skin and protects against UV radiation.

Previous studies have revealed that some non-coding RNAs, such as microRNAs, in melanocytes can alter and affect the synthesis of...
melanin or the development of melanoma under UV stimulation.\textsuperscript{41,52} However, the roles of IncRNAs in modulating melanocyte proliferation and melanogenesis are still unclear. Growing studies in recent years have characterized some important IncRNAs in controlling melanocyte cell proliferation and melanin pigment production.

As demonstrated, IncRNA SPRIGHTLY (SPRY4 intronic transcript 1, SPRY4-IT1), a 703 bp cytoplasm-localized intronic IncRNA, increased human melanocyte proliferation, invasion and colony formation, and induced a multinucleated dendritic-like phenotype.\textsuperscript{53} Using RNA-Seq and mass spectrometric analysis of SPRIGHTLY-expressing cells, researchers have revealed that the aberrant expression of SPRIGHTLY in melanocytes led to the up-regulation of cell proliferation genes (such as MCM2) and down-regulation of pro-apoptotic gene (such as dipeptidyl peptidase IV). The findings provide direct evidence for the melanomagenic role of SPRIGHTLY and how it regulates cell proliferation in human melanocytes.

Recently, researchers indicated that IncRNA urothelial cancer associated 1 (UCA1), a 2314 bp cytoplasmic intergenic IncRNA, inhibited melanogenesis in human immortalized melanocytes (PIG1) and human cutaneous melanocytes (MC).\textsuperscript{54} Additionally, UCA1 can also antagonize UVB-induced pigmentation in PIG1 and MC cells. Mechanically, UCA1 negatively modulated the CREB (cAMP-responsive element-binding protein)-MITF (microphthalmia-associated transcription factor)-melanogenesis axis through inhibiting the cAMP/PKA, ERK and JNK signalling pathways in melanocytes.

Together, these results indicate that IncRNA can modulate melanocyte functions by promoting their proliferation (IncRNA SPRIGHTLY) and reducing their melanogenesis (IncRNA UCA1).

3.3 | LncRNAs affect hair growth

Hair follicles are one of the important skin appendages located in the dermal layer. Hair structure is complicated, containing an outer root sheath, an inner root sheath and a hair shaft. Hair follicle stem cells (HFSCs), which reside in a specialized region of the outer root sheath designated the bulge, are a vital cell resource of hair follicles and the epidermis.\textsuperscript{55} The differentiation and proliferation of HFSCs in hair follicles are critical for normal hair homeostasis.

IncRNA PlncRNA-1 (also referred to as CBR3-AS1), a 743 bp cytoplasmic IncRNA, promoted the proliferation and differentiation of human hair follicle stem cells (HFSCs) through upregulation of TGF-β1-mediated Wnt/β-catenin signalling pathway.\textsuperscript{56} Moreover, compared with early-passage (passage-4) dermal papilla (DP) cells from human scalp follicles, IncRNA H19, RP11-766N7.3 and HOTAIR were aberrantly expressed in late-passage (passage-10) DP cells in vitro, which resulted in reducing hair follicle reconstruction via inhibiting Wnt/β-catenin signalling pathway.\textsuperscript{57}

Collectively, these studies show that IncRNAs contribute to key processes underlying hair growth, including the proliferation and differentiation of HFSCs (IncRNA PlncRNA-1) and hair follicle reconstruction (IncRNA H19, RP11-766N7.3 and HOTAIR) in DP cells.

3.4 | LncRNAs influence wound healing and cell proliferation

Wound healing is a fundamental and physiological process required to recover the integrity of the skin after injury, which is achieved through a series of dynamic and complicated processes including inflammation, angiogenesis, coagulation, tissue formation and remodelling.\textsuperscript{58} Failure of these reparative processes leads to chronic impaired wounds, which often happen in patients with underlying disorders, such as diabetes mellitus.\textsuperscript{59} However, the processes of physiological wound healing are intricate. In addition, efficient targeted treatments for chronic impaired wounds are still lacking. It is urgently needed to further explore the underlying molecular mechanism of physiological and pathological wound healing.

LOC105372576, which was also termed wound and keratinocyte migration-associated IncRNA 1 (WAKMAR1), was a nuclear-localized, critical pro-migratory IncRNA in human wound-edge keratinocytes in vitro and human wounds ex vivo.\textsuperscript{60} Mechanistically, it exerted its pro-migratory functions through activation of E2F transcription factor 1 expression by sequestering DNMTs (DNA methyltransferases) and inhibiting methylation of E2F1 promoter. These findings identify WAKMAR1 as a DNMT-associated IncRNA in promoting keratinocyte motility and re-epithelialization, providing human-specific mechanistic insights into skin wound healing.

IncRNA H19, which was increased in diabetic mouse when the whole blood was preserved by modified preservative fluid, promoted mouse fibroblast activation and proliferation to improve wound healing.\textsuperscript{61} Mechanically, H19 could bind to HIF-1α (hypoxia-inducible factor 1 subunit alpha) gene promoter region and increase its expression by recruiting EZH2-mediated histone methylation.

Antisense non-coding RNA in the INK4 locus (ANRIL), a 2659 bp nuclear and perinuclear cytoplasmic antisense IncRNA, was down-regulated in the diabetic wound healing mouse model and high glucose-induced human lymphatic endothelial cells.\textsuperscript{62} Further functional researches indicated that ANRIL could promote lymphangiogenesis during the diabetic wound healing process via sponging miR-181a to enhance Prox1 (Prospero homeobox 1) expression.

Together, these results indicated that IncRNAs play an essential functional role in human skin wound healing. Moreover, they also exerted encouraging effects on accelerating the impaired wound healing process in diabetes.

4 | The critical role of lncRNAs in cutaneous proliferation-related diseases

Recently, dysfunctional IncRNAs, which result in aberrant keratinocyte differentiation and disturbances of epidermal homeostasis, have also been implicated in the pathogenesis of several hyperproliferative skin diseases, such as cutaneous squamous cancer, melanoma, psoriasis, hypertrophic scar and haemangioma (Figure 4).
Cutaneous squamous cell carcinoma (cSCC) is a malignant neoplasm of the skin characterized by an aberrant proliferation of keratinocytes. It is the second most common metastatic skin cancer, with a worldwide increasing incidence. Understanding the potential pathology of cSCC will aid in development of effective treatments for cSCC.

To understand the role of lncRNAs in cSCC, Schapoor Hessam and his team performed a human-related lncRNA microarray and identified 1516 significantly upregulated and 2586 downregulated lncRNAs in cSCC biopsies comparing with non-lesional epithelial skin.63 These results can serve as a template for further, larger functional, in-depth analyses regarding cSCC-associated lncRNAs. In addition, TINCR, which was identified as an epidermal differentiation-related lncRNA, was downregulated in human squamous cell carcinoma specimens.48 A new study from Minna Piipponen provided evidence that LINCO0162, which was also named p38-inhibited cutaneous squamous cell carcinoma-associated lincRNA (PICSAR), was a specifically upregulated cytoplasmic intergenic lncRNA in primary and metastatic cSCC cell lines in vitro and cSCC tumour cells in vivo. It promoted the proliferation and migration of cSCC cells by activation of ERK1/2 signalling pathway as well as downregulation of α2β1 and α5β1 integrin.64,65

In summary, these findings improve the current knowledge that lncRNAs might serve as important mechanistic drivers in cSCC. Beyond this, these works also show significant potentials for...
the diagnosis and treatment of cSCCs by targeting dysfunctional lncRNAs.

### 4.2 LncRNAs in melanoma

Melanoma is the most lethal cutaneous cancer, with rapid progression and high metastasis potential and recurrence around the world. It is very urgent to develop novel therapeutic strategy by figuring out the underlying pathogenesis of melanoma. Recently, thanks to the advanced developments of biological technology, several lncRNAs have been identified to play vital roles in melanomagenesis (Table 2).

Antisense non-coding RNA in the INK4 locus (ANRIL), a 2659 bp nuclear and perinuclear cytoplasmic antisense lncRNA, is identified to co-cluster with ARF (also known as p14ARF or cyclin-dependent kinase inhibitor 2A) in a melanoma-neural system tumour family. In another study, ANRIL was shown to be upregulated whereas INK4A and INK4B were downregulated in cutaneous melanoma tissues and melanoma cell lines. Interestingly, knockdown of ANRIL restored INK4A and INK4B expression and inhibited colony formation and migration in vitro and growth of melanoma xenograft in vivo.

Focally amplified lncRNA on chromosome 1 (FALEC), a 566 bp nuclear intergenic lncRNA, served as an oncogenic lncRNA in human melanoma. Functional assays showed that silenced FALEC suppressed the proliferation of melanoma cells, resulting in cell cycle arrest and apoptosis. Mechanically, we discovered that FALEC boosted melanoma progression by epigenetically repressing p21 through recruiting EZH2 to the promoter of p21.

Survival-associated mitochondrial melanoma-specific onco-genic non-coding RNA (SAMMSON), a recently annotated 2027 bp cytoplasmic intergenic lncRNA with its coding gene located on chromosome 3p13-3p14, harbouried the melanoma-specific onco-gene MITF. Functional assays showed that exogenous SAMMSON increased the clonogenic potential in melanoma cell lines Mel501 and SK-MEL-28, whereas SAMMSON knockdown drastically decreased melanoma cell viability and sensitized melanoma to MAPK-targeting therapeutics in vitro and in patient-derived xenograft models. Mechanistically, SAMMSON interacted with p32, a master regulator of mitochondrial homeostasis and metabolism, to increase its mitochondrial targeting and pro-oncogenic function. These results indicate that silencing of the lineage addiction onco-gene SAMMSON disrupts vital mitochondrial functions in a cancer cell-specific manner. Targeting SAMMSON is therefore expected to deliver highly effective and tissue-restricted anti-melanoma therapeutic responses.

SRA-like non-coding RNA (SLNCR1), an abundantly expressed nuclear intergenic lncRNA associated with decreased melanoma patient survival, increased melanoma invasion. Using the sensitive technique RNA-associated transcription factor array (RATA), researchers showed that the brain-specific homeobox protein 3a (Brn3a) and the androgen receptor (AR) bound within and adjacent to SLNCR1’s conserved region, respectively. SLNCR1, AR and Brn3a were specifically required for transcriptional activation of matrix metalloproteinase 9 (MMP9) and increased melanoma invasion. These observations directly link AR to melanoma invasion.
possibly explaining why males experience more melanoma metastases and have an overall lower survival in comparison with females.

HOX transcript antisense RNA (HOTAIR), a 2364 bp nuclear antisense lncRNA, was overexpressed in primary melanoma and matched lymph node metastatic tissues.\(^{71}\) Interestingly, HOTAIR was also detected in the serum of selected metastatic patients.\(^{72}\) Mechanically, HOTAIR promoted the proliferation, invasion and migration of melanoma cells by acting as a competitive endogenous RNA (ceRNA) for miR-152-3p.\(^{73}\)

High expression in hepatocellular carcinoma long non-coding RNA (HEIH), a highly expressed nuclear and cytoplasmic intergenic IncRNA in human melanoma lesion and cell lines A375, could promote melanoma cell proliferation, invasion and migration through repression of miR-200b/a/429 transcription.\(^{74}\)

HOXA11 antisense RNA (HOXA11-AS), a 1628 bp nuclear antisense IncRNA, was overexpressed in uveal melanoma (UM) tissues from patients and cell lines OCM-1A, MUM-2C, C918 and MUM-28. It could promote UM cell proliferation and invasion and inhibit apoptosis. Mechanistically, RNA immune precipitation demonstrated that HOXA11-AS could simultaneously interact with EZH2 to suppress its target p21 protein expression. In addition, HOXA11-AS also functioned as a molecular sponge for miR-124. Overexpression of miR-124 attenuated the proliferation and invasion-promoting effect of HOXA11-AS.\(^{75}\) Collectively, these findings reveal an oncogenic role for HOXA11-AS in UM tumorigenesis.

Recently, the study found that lncRNA ILF3-AS1 (a 2032 bp cytoplasmic antisense IncRNA), which was correlated with poor prognosis of melanoma patients, was upregulated in human melanoma tissues and human melanoma cell lines SK-MEL-2, SK-MEL-28 and A375. Mechanistically, ILF3-AS1 promoted melanoma cell proliferation, migration and invasion via repressing miR-200b/a/429 expression by promoting the binding of EZH2 to their promoter.\(^{76}\)

MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), a prominent nuclear-enriched intergenic IncRNA with 8302 nucleotides in length, is initially identified as a prognostic marker for lung cancer metastasis. Accumulating studies now have demonstrated that MALAT1 promoted human melanoma cell proliferation, invasion and migration by acting as ceRNA. As an endogenous sponge, MALAT1 upregulated integrin β1 by downregulating miR-183.\(^{77}\) In addition, MALAT1 increased Slug and ADAM10 expression by silencing of miR-140.\(^{78}\) Moreover, MALAT1 modulated MMP14 and Snail by sponging miR-22.\(^{79}\)

In addition, studies have shown that the expression of IncRNA plasmacytoma variant translocation 1 (PVT1), an intergenic IncRNA diffusing throughout the nucleus and cytoplasm, was significantly upregulated in human melanoma tissues and was associated with poor prognosis. Bioinformatics analysis and dual-luciferase reporter assays revealed that PVT1 acted as a carcinogenic IncRNA by sponging tumour suppressor miR-26b.\(^{80}\)

Taken together, these studies indicate that dysfunctional IncRNAs have oncogenic effects on the pathology of melanoma.

### 4.3 LncRNAs in psoriasis

Psoriasis is a multifactorial, hyperproliferative, chronic inflammatory skin disease that affects 1%-3% of the world’s population. Gene expression changes contribute to abnormal proliferation and differentiation of basal keratinocytes in psoriasis lesions. In addition to genes encoding proteins with characterized functions, emerging evidence indicates that lncRNAs also play a vital role in psoriasis.

At first, psoriasis susceptibility–related gene induced by stress (PRINS) was found to be overexpressed in the uninvolved epidermis of psoriatic patients compared with both psoriatic lesional and healthy epidermis, suggesting a role for PRINS in psoriasis susceptibility. As reported, stress signals, such as UVB irradiation, viral infection (herpes simplex virus) and translational inhibition, can increase the RNA level of PRINS. High levels of PRINS expression in psoriatic non-lesional keratinocytes led to alteration of the stress response in non-lesional epidermis and contributed to psoriasis pathogenesis.\(^{81,82}\) Mechanistically, PRINS may contribute to psoriasis by decreasing sensitivity to spontaneous keratinocyte apoptosis via the regulation of G1P3.\(^{83}\)

Due to progress in genome sequencing, high-throughput complementary RNA-Seq has been used to reveal the differential expression profiles of IncRNAs in normal and psoriatic skin. First, Sebo Withoff provided us with an overview that many transcripts were enriched in autoimmune and immune-related disorders (AID). The observed enrichment of IncRNA transcripts in AID loci implies that IncRNAs might play an important role in AID aetiology and suggests that these differential IncRNAs in AID should be studied in more detail correctly to interpret genome-wide association study (GWAS) findings.\(^{83}\)

Then, James T Elder and his team used RNA-Seq to analyse 99 lesional psoriatic, 27 uninvolved psoriatic and 90 normal skin biopsies. They detected 2942 previously annotated and 1080 novel IncRNAs, which were expected to be skin-specific. Their results indicated that many IncRNAs, in particular those that were differentially expressed, were co-expressed with genes involved in immune-related functions. Additionally, novel IncRNAs were enriched in the epidermal differentiation complex. They also identified distinct tissue-specific expression patterns and epigenetic profiles for novel IncRNAs. Together, these results indicate that great deals of IncRNAs are involved in the immune pathogenesis of psoriasis.\(^{84}\)

In addition, Wilson Liao and his team characterized the landscape of IncRNAs in healthy (NN) and psoriatic skin. They also studied the IncRNA transcriptome in lesional skin biopsy samples from psoriasis patients before (PP) and after treatment (PT) with adalimumab. This research identified the differential expression of 971 IncRNAs between PP and NN, 157 between PP and PT, and 377 between PT and NN. Liao’s findings highlight the potential importance of IncRNAs in the pathology of psoriasis and their response to the treatment with adalimumab.\(^{85}\) Additionally, Wilson Liao applied weighted gene co-expression network analysis (WGCNA) to analyse the RNA-Seq data from psoriasis patients and healthy controls. Network analysis
revealed previously unreported biological pathways and roles for coding genes and lncRNAs in psoriasis.\textsuperscript{86}

Recently, researchers have suggested that the cytoplasmic IncRNA Msh homeobox 2 pseudogene 1 (MSX2P1) was upregulated in clinical psoriatic lesions compared with normal healthy skin tissues, human immortalized keratinocyte cells and normal human epidermal keratinocyte cells. LncRNA MSX2P1 facilitated the progression and growth of IL-22-stimulated keratinocytes by serving as an endogenous sponge directly binding to miR-6731-5p and activating S100A7. We speculate that the biological network of MSX2P1-miR-6731-5p-S100A7 might be a potential novel therapeutic target for the future treatment of psoriasis.\textsuperscript{87}

In summary, these sequencing results show the differential expression profiles of IncRNAs between healthy and psoriatic skin. Moreover, functional studies indicate that IncRNAs are important contributors to key processes in psoriasis. Furthermore, these results also provide a novel basis for the development of diagnostic and treatment options for patients with psoriasis.

4.4 | LncRNAs in hypertrophic scar

Hypertrophic scar (HS), a pathological response to skin wound healing, is characterized by the invasive growth of fibroblasts and the excessive deposition of collagen.\textsuperscript{98,89} It is a common and inevitable outcome of deep skin trauma or severe burn injury. The overall incidence of hypertrophic scars for skin trauma is 40%-70%, whereas the incidence of burn scars is as high as 80%.\textsuperscript{90} Hypertrophic scars can significantly affect the health of patients via causing pain, pruritus and contractures. Therefore, a thorough understanding of the pathophysiology of HS may help to improve the treatment strategy for HS. Recently, growing evidence suggests that IncRNAs are involved in the occurrence and development of hypertrophic scar.

AC067945.2 (also called NONHSAT076109 in NONCODEv5), a 623 bp antisense IncRNA, was downregulated by transforming growth factor-β1 (TGF-β1) in hypertrophic scar tissues compared to corresponding matched normal skin tissues. Mechanistically, AC067945.2 can significantly promote early apoptosis and reduce the expression of COL1A1, COL1A2, COL3A1 and α-SMA in normal skin fibroblasts. Therefore, downregulated AC067945.2 in hypertrophic scar tissues contributed to the pathological hypertrophic scar formation via inhibiting fibroblast apoptosis and promoting extracellular matrix deposition.\textsuperscript{91}

On the other hand, IncRNAs might be negative regulators to hypertrophic scar. COL1A2-AS1 (also named IncRNA8975-1), a 352 bp antisense IncRNA, was overexpressed in hypertrophic scar tissues and corresponding hypertrophic scar fibroblasts. It might serve as a negative modulator by inhibiting fibroblast proliferation and reducing COL1A2, COL1A1, COL3A1 and α-SMA expression in the process of hypertrophic scar.\textsuperscript{92}

Together, IncRNAs may play a double-sided role in the pathological process of hypertrophic scar. Further studies are needed to elaborate precise effects of lncRNAs on hypertrophic scar.

4.5 | LncRNAs in haemangioma

Haemangioma (HA), which is the most common benign vascular neoplasm of premature infants and infants with low birthweight, is resulted from abnormal proliferation of endothelial cells.\textsuperscript{93,94} It threatens the lives of young children for its high speed in growth or invasion. Therefore, it is urgent to do more research to figure out the pathogenesis of haemangioma. Current advances in the identification of long non-coding RNAs and their interaction with their target genes have enhanced our awareness of HA pathogenesis.

CASC9 (cancer susceptibility candidate 9), a 1.4 kb cytoplasmic intergenic IncRNA, was obviously overexpressed in human proliferating phase (rapid growth) HA tissues than that in involuting phase (spontaneous regression) HA tissues and normal tissues.\textsuperscript{95} Further studies indicated that CASC9 accelerated the proliferation, invasion and migration of HA-derived endothelial cell (HDECs) via negatively regulating miR-125a-3p/Nrg1 (neuregulin 1) axis.

OIP5-AS1, a 1.7 kb cytoplasmic antisense IncRNA, was upregulated in both human involuting and proliferating phase haemangioma tissues.\textsuperscript{96} Accumulating results indicated that OIP5-AS1 promoted the proliferation of human haemangioma vascular endothelial cells (HVECs) via regulating miR-195-5p/NOB1 (NIN1 binding protein 1 homolog) axis.

SNHG16 (snoRNA host gene 16), a 2.4 kb cytoplasm-localized sense-overlapping long non-coding RNA, was obviously higher in human proliferating phase HA tissues than that in involuting phase HA tissues and normal tissues.\textsuperscript{97} Mechanically, upregulated SNHG16 drives proliferation, migration and invasion of HVECs through modulation of miR-520d-3p/STAT3 axis.

NEAT1 (nuclear-enriched abundant transcript 1), a 3.7 kb nuclear paraspeckle-localized intergenic IncRNA, was elevated in human HA tissues, especially in proliferating phase Has.\textsuperscript{98} Further mechanism demonstrated that NEAT1 facilitated the progression of haemangioma via functioning as a ceRNA for miR-361-5p to regulate VEGFA expression.

In addition, IncRNAs were also indicated to function as negative regulators on HA proliferation. LncRNA MEG3 (maternally expressed gene 3), a 1.6 kb intergenic IncRNA, can inhibit human HA tumorigenesis by sponging miR-494 and regulating PTEN/PI3K/AKT pathway.\textsuperscript{99} However, the expression of MEG3 was obviously downregulated in proliferating phase human HAs, which eventually promoted the development of HAs.

In summary, these studies indicate that dysfunctional IncRNAs might be vital contributors to the pathology of haemangioma.

5 | POTENTIAL DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF LNCRNAS

Advances in the identification and characterization of long non-coding RNA in dermatological research enhance our understanding of the significance of regulatory non-coding RNAs in skin development and homeostasis and their implication in regulation of a variety of
skin pathological conditions. The tissue- or disease-specific expression of lncRNAs makes them ideal biomarkers.

5.1 | Biomarkers for the diagnosis and prognosis of skin diseases

The tissue- and disease-specific expression of lncRNAs makes them ideal biomarkers for diagnosis. For example, PICSAR is proved to be specifically expressed by tumour cells in actinic keratosis (UV-induced premalignant lesions), cSCC in situ and invasive cSCCs but not by keratinocytes in normal skin in vivo, suggesting PICSAR as a specific biomarker for early diagnose of primary and invasive cSCC.65 Besides their potential diagnostic implications, lncRNAs could also be used as molecular marker to predict prognosis of cutaneous disorders. Dysfunctional lncRNAs, such as FALEC, HEIH, SLNCR1 and HOTAIR, predict poor outcome in melanoma patients.68,70,73,74 Additionally, HOTAIR can also be identified in the serum. The identification of lncRNAs in the blood might suggest its use as a non-invasive circulating marker for diagnosing cutaneous diseases or as a marker of relapses during the follow-up.72 Moreover, lncRNAs can also act as biomarkers to predict the pathological stages of benign skin diseases. For example, the high level of lncRNA CAS9, SNHG16 and NEAT1 in haemangioma tissues predicts that haemangioma is on the proliferating phase rather than involuting phase. As the Liao’s findings, the differential lncRNAs can also be used as biomarkers to monitor and predict the therapeutic responses to the treatment with adalimumab.84 Overall, these results indicate that lncRNAs could serve as particularly useful biomarkers for diagnosis and prognosis of cutaneous disorders (Table 3).

5.2 | Therapeutic strategies for skin diseases

Given the importance of lncRNA in skin diseases, lncRNAs might be promising therapeutic targets for treatments. Recent research has demonstrated that lncRNAs can be knocked down via the utilization
of RNA interference (RNAi).

Most recently, utilizing or developing new and cutting-edge technologies, such as antisense oligonucleotide (ASO), locked nucleic acid (LNA) or bridged nucleic acid (BNA) technologies, and CRISPR-mediated gene editing, will aid in targeting the dysfunctional lncRNAs for their therapeutic values. Excitingly, targeting the lncRNA MALAT1 via LNA gampmR ASO has recently been indicated to trigger anti-multiple myeloma activities, providing proof of concept that the therapeutic potential of targeting lncRNAs.

Thus, targeting lncRNAs will be a promising therapeutic strategy for skin diseases.

6 CONCLUSIONS AND FUTURE PERSPECTIVE

Cutaneous biology and skin disease–related lncRNAs are still an emerging field, with only a few of them being characterized for their biological functions and clinical implications. This review summarizes the current knowledge regarding the promotive or inhibitory regulations of lncRNAs to skin development and epidermal homeostasis. Besides, this review also describes the pathogenic role of dysfunctional lncRNAs in hyperproliferative skin diseases.

However, there are many mysteries remaining, including whether the evolution of lncRNAs is conserved. Given that lncRNAs within distinct model animals do not show strict homology, future studies need to focus on the in vivo biological functions of cutaneous lncRNAs.

In addition, the functional sequences and domains that execute the functions of lncRNAs remain to be fully investigated. In future, using artificial intelligence or neural network, researchers may precisely predict the binding between lncRNAs and proteins. Moreover, with the development of cross-linking methods, such as capture hybridization analysis of RNA targets (Chart), photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation (PAR-CLIP) and individual nucleotide resolution UV cross-linking and immunoprecipitation (iCLIP), researchers can map the network of interactions that the lncRNA establishes with DNA, RNA and proteins. Furthermore, structure-related technologies, such as selective 2′-hydroxyl acylation analysed by primer extension (SHAPE), will provide detailed evidences to understand structure-function interrelationships for lncRNAs.

There are also some challenges of using lncRNAs as biomarkers. For instance, the amount of lncRNAs in plasma is generally low. Therefore, unlike short non-coding RNAs, such as miRNAs, most lncRNAs are not detectable in plasma by standard methods, such as microarrays or quantitative PCR. More studies are required to examine whether lncRNAs are better predictive biomarkers than protein-coding genes or other non-coding RNAs (such as miRNAs).

Additionally, the full potential of using lncRNAs in skin disease therapy has not yet been fully explored now. Better understanding of precise biological functions of lncRNAs and better targeting technologies are required, which will advance the lncRNA therapy.

In future, more and more clinical trials targeting various lncRNAs are ongoing for the treatment with cutaneous diseases.

6 CONCLUSIONS AND FUTURE PERSPECTIVE

Cutaneous biology and skin disease–related lncRNAs are still an emerging field, with only a few of them being characterized for their biological functions and clinical implications. This review summarizes the current knowledge regarding the promotive or inhibitory regulations of lncRNAs to skin development and epidermal homeostasis. Besides, this review also describes the pathogenic role of dysfunctional lncRNAs in hyperproliferative skin diseases.

However, there are many mysteries remaining, including whether the evolution of lncRNAs is conserved. Given that lncRNAs within distinct model animals do not show strict homology, future studies need to focus on the in vivo biological functions of cutaneous lncRNAs.

In addition, the functional sequences and domains that execute the functions of lncRNAs remain to be fully investigated. In future, using artificial intelligence or neural network, researchers may precisely predict the binding between lncRNAs and proteins. Moreover, with the development of cross-linking methods, such as capture hybridization analysis of RNA targets (Chart), photoactivatable ribonucleoside-enhanced cross-linking and immunoprecipitation (PAR-CLIP) and individual nucleotide resolution UV cross-linking and immunoprecipitation (iCLIP), researchers can map the network of interactions that the lncRNA establishes with DNA, RNA and proteins. Furthermore, structure-related technologies, such as selective 2′-hydroxyl acylation analysed by primer extension (SHAPE), will provide detailed evidences to understand structure-function interrelationships for lncRNAs.

There are also some challenges of using lncRNAs as biomarkers. For instance, the amount of lncRNAs in plasma is generally low. Therefore, unlike short non-coding RNAs, such as miRNAs, most lncRNAs are not detectable in plasma by standard methods, such as microarrays or quantitative PCR. More studies are required to examine whether lncRNAs are better predictive biomarkers than protein-coding genes or other non-coding RNAs (such as miRNAs).

Additionally, the full potential of using lncRNAs in skin disease therapy has not yet been fully explored now. Better understanding of precise biological functions of lncRNAs and better targeting technologies are required, which will advance the lncRNA therapy.

In future, more and more clinical trials targeting various lncRNAs are ongoing for the treatment with cutaneous diseases.

ACKNOWLEDGEMENTS

We appreciate Professor Chuanjian Lu, Professor Boudewijn Burgering and Runyue Huang for their assistance in this article modification. This study was supported by the National Natural Science Foundation of China (No. 81602748); Natural Science Foundation of Guangdong Province (No. 2016A030310291, No. 2017A030313639); The Specific Research Fund for TC Science and Technology of Guangdong Provincial Hospital of Chinese Medicine (YN2015QN03, YN2016YX03, YN2018QJ03); and Medical Scientific Research Foundation of Guangdong Province (No. A2017277).

CONFLICT OF INTEREST

The authors have declared no conflicting interests.

AUTHOR CONTRIBUTIONS

LT, YL and HX wrote the manuscript; YL, XY and HX searched the literature; LT and GZ edited the paper.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Lipeng Tang https://orcid.org/0000-0002-8760-9331
Guangjuan Zheng https://orcid.org/0000-0001-5570-2470

REFERENCES

1. Ramot Y, Mastrofrancesco A, Camera E, Desreumaux P, Paus R, Ricardo M. The role of PPAR gamma-mediated signaling in skin biology and pathology: new targets and opportunities for clinical dermatology. Exp Dermatol. 2015;24(4):245-251.
2. Tellkamp F, Vorhagen S, Niessen CM. Epidermal polarity genes in health and disease. Cold Spring Harb Perspect Med. 2014;4(12):a015255.
3. Harrow J, Frankish A, Gonzalez JM, et al. GENCODE: the reference human genome annotation for The ENCODE Project. Genome Res. 2012;22(9):1760-1774.
4. Miller DF, Yan PX, Fang F, et al. Stranded whole transcriptome RNA-Seq for all RNA types. Curr Protoc Hum Genet. 2015;84:11.14.1-23.
5. St. Laurent G, Wahlstedt C, Kapranov P. The landscape of long noncoding RNA classification. Trends Genet. 2015;31(5):239-251.
6. Shi Z, Montgomery TA, Qi Y, Ruvkun G. High-throughput sequencing reveals extraordinary fluidity of miRNA, piRNA, and siRNA pathways in nematodes. Genome Res. 2013;23(3):497-508.
7. Flynn RA, Chang HY. Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell. 2014;14(6):752-761.
8. Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet. 2016;17(1):47-62.

9. Kondo Y, Shinjo K, Katsushima K. Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Sci. 2017;108(10):1927-1933.

10. Gomez JA, Wapinski OL, Yang YW, et al. The NeST long ncRNA controls microbial susceptibility and epigenetic activation of the interferon-gamma locus. Cell. 2013;152(4):743-754.

11. Atianand MK, Hu W, Satpathy AT, et al. A long noncoding RNA lin-cRNA-EPS acts as a transcriptional brake to restrain inflammation. Cell. 2016;165(7):1672-1685.

12. Tan Justin L, Fogley Rachel D, Flynn Ryan A, et al. Stress from nucleotide depletion activates the transcriptional regulator HEXIM1 to suppress melanoma. Mol Cell. 2016;62(1):34-46.

13. Dykes IM, Emanuelli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2015;13(5):177-186.

14. Weng R, Lu C, Liu X, et al. Long noncoding RNA-1648 orchestrates neural differentiation through the miR-200c/ZEB axis. Stem Cells. 2018;36(3):325-336.

15. Xiao L, Wu J, Wang JY, et al. Noncoding RNA uc.173 promotes renewal of the intestinal mucosa by inducing degradation of MicroRNA 195. Gastroenterology. 2018;154(3):599-611.

16. Chen YG, Satpathy AT, Chang HY. Gene regulation in the immune system by long noncoding RNAs. Nat Immunol. 2017;18(9):962-972.

17. Zhang Y, Cao X. Long noncoding RNAs in innate immunity. Cell Mol Immunol. 2016;13(2):138-147.

18. Fatica A, Bozzi I. Long non-coding RNAs: new players in cell differentiation and development. Nat Rev Genet. 2014;15(1):7-21.

19. Huarte M. The emerging role of IncRNAs in cancer. Nat Med. 2015;21(11):1253-1261.

20. Tang Y, Zhou T, Yu X, Xue Z, Shen N. The role of long noncoding RNAs in rheumatic diseases. Nat Rev Rheumatol. 2017;13(11):657-669.

21. Antonini D, Molto MR, Missero C. Research techniques made simple: identification and characterization of long noncoding RNA in dermatological research. J Invest Dermatol. 2017;137(3):e21-e26.

22. Botchkareva NV. The molecular revolution in cutaneous biology: noncoding RNAs: new molecular players in dermatology and cutaneous biology. J Invest Dermatol. 2017;137(5):e105-e111.

23. Wan DC, Wang KC. Long noncoding RNA: significance and potential in skin biology. Cold Spring Harb Perspect Med. 2014;4(5):a015404.

24. Ma L, Bajic VB, Zhang Z. On the classification of long non-coding RNAs. RNA Biol. 2013;10(6):925-933.

25. Froberg JE, Yang L, Lee JT. Guided by RNAs: X-inactivation as a model for IncRNA function. J Mol Biol. 2013;425(19):3698-3706.

26. Kanduri C. Long noncoding RNAs: lessons from genomic imprinting. Biochem Biophys Acta. 2016;1859(1):102-111.

27. Xu TP, Liu XX, Xia R, et al. SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. Oncogene. 2015;34(45):5648-5661.

28. Kleaveland B, Shi CY, Stefano J, Bartel DP. A network of non-coding regulatory RNAs acts in the mammalian brain. Cell. 2018;174(2):350-362.e317.

29. Li X, Wang X, Song W, et al. Oncogenic properties of NEAT1 in prostate cancer cells depend on the CDC5L-AGRN transcriptional regulation circuit. Can Res. 2018;78(15):4138-4149.

30. Gonzalez I, Munita R, Agirre E, et al. An IncRNA regulates alternative splicing via establishment of a splicing-specific chromatin signature. Nat Struct Mol Biol. 2015;22(5):370-376.

31. Wang K, Long B, Zhou LY, et al. CARL IncRNA inhibits anoxia-induced mitochondrial fission and apoptosis in cardiomyocytes by impairing miR-539-dependent PHB2 downregulation. Nat Commun. 2014;5:3596.

32. Yoon J-H, Abdelmohsen K, Gorospe M. Posttranscriptional gene regulation by long noncoding RNA. J Mol Biol. 2013;425(19):3723-3730.

33. Blanpain C, Fuchs E. Epidermal homeostasis: a balancing act of stem cells in the skin. Nat Rev Mol Cell Biol. 2009;10(3):207-217.

34. Horsburgh S, Fullard N, Roger M, et al. MicroRNAs in the skin: role in development, homeostasis and regeneration. Clin Sci. 2017;131(15):1923-1940.

35. Luan L, Shi J, Yu Z, Andl T. The major miR-31 target genes STK40 and LAT52 and their implications in the regulation of keratinocyte growth and hair differentiation. Exp Dermatol. 2017;26(6):497-504.

36. Yu N, Yang Y, Li X, et al. MiR-26a inhibits proliferation and migration of HaCaT keratinocytes through regulating PTEN expression. Gene. 2016;594(1):117-124.

37. Barbolla-Boutrand L, Joly-Tonetti N, Dos Santos M, et al. MicroRNA-23b-3p regulates human keratinocyte differentiation through repression of TGF1 and activation of the TGF-ss-MC2 signalling pathway. Exp Dermatol. 2017;26(1):51-57.

38. He Y, Xu H, Li C, et al. Nicarstrin/miR-30a-3p/RAB31 axis regulates keratinocyte differentiation by impairing EGFR signaling in familial acrosclerosis. J Invest Dermatol. 2019;139(1):124-134.

39. YIR, Poy MN, Stoffel M, Fuchs E. A skin microRNA promotes differentiation by repressing 'stemness'. Nature. 2008;452(7184):225-229.

40. Jiang P, Zhang J, et al. MicroRNA 143-5p regulates alpha melanocyte migration, proliferation and melanogenesis. Exp Dermatol. 2018;27(2):166-171.

41. Lin KY, Chen CM, Lu CY, et al. Regulation of miR-21 expression in human melanoma via UV-induction of melanin pigmentation. Environ Toxicol. 2017;32(8):2064-2069.

42. Mione M, Bossendorff A. MicroRNAs in melanocyte and melanoma biology. Pigment Cell Melanoma Res. 2015;28(3):340-354.

43. Ahmed M, Alam M, Emelianov VU, et al. MicroRNA-214 controls skin and hair follicle development by modulating the activity of the Wnt pathway. J Cell Biol. 2014;207(4):549-567.

44. Yan S, Yu Z, Ning L, et al. Let-7b promotes alpaca hair growth via transcriptional repression of TGFβRI. Gene. 2016;577(1):32-36.

45. Li X, Guo L, Liu Y, et al. MicroRNA-21 promotes wound healing via the Smad7-Smad2/3-Elastin pathway. Exp Cell Res. 2018;362(2):245-251.

46. Li D, Wang A, Liu X, et al. MicroRNA-132 enhances transition from inflammation to proliferation during wound healing. J Clin Invest. 2015;125(8):3008-3026.

47. Mazar J, Sinha S, Dinger ME, Mattick JS, Perera RJ. Protein-coding and non-coding gene expression analysis in differentiating human keratinocytes using a three-dimensional epidermal equivalent. Mol Genet Genom: MGG. 2010;284(1):1-9.

48. Kretz M, Siprashvili Z, Chu C, et al. Control of somatic tissue differentiation by the long non-coding RNA TINCR. Nature. 2012;493(7431):231-235.

49. Kretz M, Webster DE, Flockhart RJ, et al. Suppression of progenitor differentiation requires the long noncoding RNA ANCR. Genes Dev. 2012;26(4):338-343.

50. Li C-X, Li H-G, Huang L-T, et al. H19 IncRNA regulates keratinocyte differentiation by targeting miR-130b-3p. Cell Death Dis. 2017;8(11):e3174.

51. Yamaguchi Y, Hearing VJ. Melanocytes and their diseases. Cold Spring Harb Perspect Med. 2014;4(5):a017046-a017046.

52. Sha J, Gastman BR, Morris N, et al. The response of microRNAs to solar UV in skin-resident melanocytes differs between melanoma patients and healthy persons. PLoS ONE. 2016;11(5):e0154915.

53. Zhao W, Mazar J, Lee B, et al. The long noncoding RNA SPRIGHTLY regulates cell proliferation in primary human melanocytes. J Invest Dermatol. 2016;136(4):819-828.

54. Pei S, Chen J, Lu J, et al. The long noncoding RNA UCA1 negatively regulates melanogenesis in melanocytes. J Invest Dermatol. 2019.
55. Nowak JA, Polak L, Pasolli HA, Fuchs E. Hair follicle stem cells are specified and function in early skin morphogenesis. Cell Stem Cell. 2008;3(1):33-43.

56. Si Y, Bai J, Wu J, et al. LncRNA PincRNA1 regulates proliferation and differentiation of hair follicle stem cells through TGFbeta1 mediated Wnt/beta catenin signal pathway. Mol Med Rep. 2018;17(1):1191-1197.

57. Lin C-M, Liu Y, Huang K, et al. Long noncoding RNA expression in dermal papilla cells contributes to hairy gene regulation. Biochem Biophys Res Comm. 2014;453(3):508-514.

58. Reinke JM, Ennis WJ, Koh TJ. Diabetes medications: impact on inflammation and wound healing. J Diabetes Complications. 2016;30(4):746-752.

59. Lie S, Kular L, Vj M, et al. Human skin long noncoding RNA WAKMAR1 regulates wound healing by enhancing keratinocyte migration. Proc Natl Acad Sci. 2019;116(19):9443-9452.

60. Guo J-R, Yin L, Chen Y-Q, et al. Autologous blood transfusion augments impaired wound healing in diabetic mice by enhancing IncRNA H19 expression via the HIF-1α signaling pathway. Cell Commun Signal. 2018;16(1):84.

61. He Z-Y, Wei T-H, Zhang P-H, Zhou J, Huang X-Y. Long non-coding RNA-antisense noncoding RNA in the INK4 locus accelerates wound healing in diabetes by promoting lymphan-giogenesis via regulating miR-181a/Prox1 axis. J Cell Physiol. 2019;234(4):4627-4640.

62. Sand M, Bechara FG, Sand D, et al. Expression profiles of long non-coding RNAs in cutaneous squamous cell carcinoma. Epigenomics. 2016;8(4):501-518.

63. Piipponen M, Heino J, Kahari VM, Nissinen L. Long non-coding RNA PICSAR decreases adhesion and promotes migration of squamous cell carcinoma cells by downregulating alpha2beta1 and alpha5beta1 integrin expression. Biol Open. 2018;7(11). pii: bio037044.

64. Piipponen M, Nissinen L, Farshchian M, et al. Long noncoding RNA PICSAR promotes growth of cutaneous squamous cell carcinoma by regulating ERK1/2 activity. J Invest Dermatol. 2016;136(8):1701-1710.

65. Pasmant E, Laurendeau I, Heron D, et al. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Can Res. 2007;67(8):3963-3969.

66. Xu S, Wang H, Pan H, et al. ANRIL IncRNA triggers efficient therapeutically efficacious reprogramming of the aberrant INK4-hub in melanoma. Cancer Lett. 2016;381(1):41-48.

67. Ni N, Song H, Wang X, Xu X, Jiang Y, Sun J. Up-regulation of long noncoding RNA PALEC predicts poor prognosis and promotes melanoma cell proliferation through epigenetically silencing p21. Biomed Pharmacotherapy = Biomedecine pharmacotherapie. 2017;96:1371-1379.

68. Leucci E, Vendramin R, Spinazzi M, et al. Melanoma addiction to the long non-coding RNA SAMMSON. Nature. 2016;531(7595):518-522.

69. Schmidt K, Joyce CE, Buquicchio F, et al. The IncRNA SLNCR1 mediates melanoma invasion through a conserved SRA1-like region. Cell Rep. 2016;15(9):2025-2037.

70. Tang L, Zhang W, Su B, Yu B. Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. Biomed Res Int. 2013;2013:251098.

71. Cantile M, Scognamiglio G, Marra L, et al. HOTAIR role in melanoma progression and its identification in the blood of patients with advanced disease. J Cell Physiol. 2017;232(12):3422-3432.

72. Wenkang Luan RL, Liu L, Ni X, et al. Long non-coding RNA HOTAIR acts as a competing endogenous RNA to promote malignant melanoma progression by sponging miR-152-3p. Oncotarget. 2017;8(49):85401-85414.

73. Zhao H, Xing G, Wang Y, Luo Z, Liu G, Meng H. Long noncoding RNA HEIH promotes melanoma cell proliferation, migration and invasion via inhibition of miR-200b/a/429. Biosci Rep. 2017;37(3):BSR20170682.

74. Lu Q, Zhao N, Zha G, Wang H, Tong Q, Xin S. LncRNA HOXA11-AS exerts oncogenic functions by repressing p21 and miR-124 in uveal melanoma. DNA Cell Biol. 2017;36(10):837-844.

75. Chen X, Liu S, Zhao X, et al. Long noncoding RNA ILF3-AS1 promotes cell proliferation, migration, and invasion via negatively regulating miR-200b/a/429 in melanoma. Biosci Rep. 2017;37(6):BSR20171031.

76. Sun Y, Cheng H, Wang G, et al. Deregulation of miR-183 promotes melanoma development via IncRNA MALAT1 regulation and ITGB1 signal activation. Oncotarget. 2017;8(2):3509-3518.

77. Sun L, Sun P, Zhou QY, Gao X, Han Q. Long noncoding RNA MALAT1 promotes uveal melanoma cell growth and invasion by silencing of miR-140. Am J Transl Res. 2016;8(9):3939-3946.

78. Luan W, Li L, Shi Y, et al. Long non-coding RNA MALAT1 acts as a competing endogenous RNA to promote malignant melanoma growth and metastasis by sponging miR-22. Oncotarget. 2016;8(2):3509-3518.

79. Wang BJ, Ding HW, Ma GA. Long noncoding RNA PVT1 promotes melanoma progression via endogenous sponging miR-26b. Oncol Res. 2018;26(5):675-681.

80. Szegedi K, Sonkoly E, Nagy N, et al. The anti-apoptotic protein G1P3 is overexpressed in psoriasis and regulated by the non-coding RNA, PRINS. Exp Dermatol. 2010;19(3):269-278.

81. Széll M, Danis J, Bata-Csorrgő Z, Kemény L. PRINS, a primate-specific long non-coding RNA, plays a role in the keratinocyte stress response and psoriasis pathogenesis. Pflügers Archiv - Eur J Physiol. 2016;468(6):935-943.

82. Hrdlickova B, Kumar V, Kanduri K, et al. Expression profiles of long non-coding RNAs located in autoimmune disease-associated regions reveal immune cell-type specificity. Genome Med. 2014;6(10):88.

83. Tsói LC, Iyer MK, Stuart PE, et al. Analysis of long non-coding RNAs highlights tissue-specific expression patterns and epigenetic profiles in normal and psoriatic skin. Genome Biol. 2015;16(1):24.

84. Gupta R, Ahn R, Lai K, et al. Landscape of long noncoding RNAs in psoriatic and healthy skin. J Invest Dermatol. 2016;136(3):603-609.

85. Ahn R, Gupta R, Lai K, et al. Network analysis of psoriasis reveals biological pathways and roles for coding and long non-coding RNAs. BMC Genom. 2016;17(1):841.

86. Qiao M, Li R, Zhao X, Yan J, Sun Q. Up-regulated IncRNA-MX2P1 promotes the growth of IL-22-stimulated keratinocytes by inhibiting miR-6731-5p and activating S100A7. Exp Cell Res. 2018;363(2):243-254.

87. Zhu Z, Ding J, Shankowsky HA, Tredget EE. The molecular mechanism of hypertrophic scar. J Cell Commun Signal. 2013;7(4):239-252.

88. Rabello FB, Souza CD, Farinha JA JR. Update on hypertrophic scar. Clinics. 2014;69(8):565-573.

89. Bombaro KM, Engrav LH, Carrougher GJ, et al. What is the prevalence of hypertrophic scarring following burns? Burns. 2003;29(4):299-302.

90. Shen L, Li J, Li Q, et al. Overexpression of LncRNA AC067945.2 down-regulates collagen expression in skin fibroblasts and possibly correlates with the VEGF and Wnt signalling pathways. Cell Physiol Biochem. 2018;45(2):761-771.

91. Li J, Chen L, Cao C, et al. The long non-coding RNA LncRNA8975-1 is upregulated in hypertrophic scar fibroblasts and controls collagen expression. Cell Physiol Biochem. 2016;40(1-2):326-334.

92. Rotter A, de Oliveira Z. Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. J Deutschen
Dermatologischen Gesellschaft J. German Soc Dermatol: JDDG. 2017;15(12):1185-1190.

94. Phung TL, Hochman M. Pathogenesis of infantile hemangioma. Facial Plast Surg: FPS. 2012;28(6):554-562.

95. Li X, Chen B, Chi D, Zhang Y, Jiang W. lncRNA CASC9 regulates cell migration and invasion in hemangioma endothelial cells by targeting miR-125a-3p/Nrg1. Oncotargets Therapy. 2019;12:423-432.

96. Dai Y, Wan Y, Qiu M, et al. lncRNA MEG3 Suppresses the progression of hemangioma via the miR-361-5p/VEGFA pathway. Biochem Biophys Res Comm. 2019;512(4):825-831.

97. Zhao W, Fu H, Zhang S, Sun S, Liu Y. lncRNA SNHG16 drives proliferation, migration, and invasion of hemangioma endothelial cell through modulation of miR-520d-3p/STAT3 axis. Cancer Med. 2018;7(7):3311-3320.

98. Yu X, Liu X, Wang R, Wang L. Long non-coding RNA NEAT1 promotes the progression of hemangioma via the miR-361-5p/VEGFA pathway. Biochem Biophys Res Comm. 2019;512(4):825-831.

99. Liu C, Cao Z, Bai Y, et al. lncRNA AK077216 promotes RANKL-induced osteoclastogenesis and bone resorption via NFATc1 by inhibition of NIP45. J Cell Physiol. 2019;234(2):1606-1617.

100. Roux BT, Lindsay MA, Heward JA. Knockdown of nuclear-located enhancer RNAs and long ncRNAs using locked nucleic acid GapmeRs. Methods Mol Biol. 2016;1402:199-213.

101. Hansmeier NR, Widdershoven P, Khani S, Kornfeld JW. Rapid generation of long noncoding RNA knockout mice using CRISPR/Cas9 technology. Non-Coding RNA. 2019;5(1):12.

102. Jiang J, Zhao T, Tian L, Li Y. LncRNA OIP5-AS1 promotes the proliferation of hemangioma vascular endothelial cells via regulating miR-195-5p/NOB1 axis. Front Pharmacol. 2019;10:449.

103. Phung TL, Hochman M. Pathogenesis of infantile hemangioma. Facial Plast Surg: FPS. 2012;28(6):554-562.

104. Roux BT, Lindsay MA, Heward JA. Knockdown of nuclear non-coding RNA with antisense oligonucleotide technology as cancer therapeutics. Non-Coding RNA. 2019;5(1):12.

105. Jackson A, Jani S, Davies-Sala C, Soler-Bistué A, Zorreguieta A, Tolmasky ME. Assessment of configurations and chemistries of bridged nucleic acids-containing oligomers as external guide sequences: a methodology for inhibition of expression of antibiotic resistance genes. Bioi Methods Protoc. 2016;1(1):bpw001.

106. Esposito R, Bosch N, Lanzós A, Polidori T, Pulido-Quetglas C, Johnson R. Hacking the cancer genome: profiling therapeutically actionable long non-coding RNAs using CRISPR-Cas9 screening. Cancer Cell. 2019;35(4):545-557.

107. Zhou T, Kim Y, MacLeod AR. Targeting long non-coding RNA with anti-sense oligonucleotide technology as cancer therapeutics. Non-Coding RNA. 2019;5(1):12.